Tumor Suppressor and Innate Immunity

Dear Colleagues,

A vaccine is not an unheard word to anyone today. The COVID pandemic made the vaccine a buzzword, harnessing the power of one´s immunity to fight infections. Although the vaccine is a century-old research area with remarkable successful examples of eradicating infectious diseases such as polio, there are more research opportunities in the field, awaiting more discoveries. As with any other research field, vaccine development also faces challenges. This special issue promotes vaccine research to address the major challenges for advancing the field and broadening the research scope. We believe that nucleic acid vaccines can serve as a powerful weapon against increasing viral infections. Therefore, discovering new vaccines and their possible genotoxic effects will discover more effective vaccines. We assume that the parallel research on defining next-generation immunogens will accelerate vaccine development. As a surrogate of the immune system, the development of predictive biomarkers can distinguish individuals who will most likely develop a strong immune response upon the vaccination. Along with the development of mainstream vaccinations, we think that technological advancements provide a platform for vaccine development.

Dr. Markus Vähä-Koskela
Dr. Disha Malani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Next-generation vaccines
• Immunogens